| 1 |
35021069 | Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. | 2022 Mar |
2 |
| 2 |
35041175 | Asciminib: First Approval. | 2022 Feb |
2 |
| 3 |
35129779 | Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. | 2022 Apr |
2 |
| 4 |
35468180 | Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. | 2022 Jun 16 |
1 |
| 5 |
35583386 | An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors. | 2022 Jun |
1 |
| 6 |
35616006 | Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents. | 2022 May 26 |
2 |
| 7 |
33971041 | Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib. | 2021 Aug 1 |
1 |
| 8 |
34115385 | Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment. | 2021 Nov |
1 |
| 9 |
34659899 | Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. | 2021 |
5 |
| 10 |
32380976 | The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib. | 2020 May 7 |
1 |
| 11 |
32657579 | Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. | 2020 Aug 13 |
1 |
| 12 |
33096322 | The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. | 2020 Nov |
7 |
| 13 |
30927708 | Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL. | 2019 Jun |
4 |
| 14 |
31250767 | The Perplexity of Synergistic Duality: Inter-molecular Mechanisms of Communication in BCR-ABL1. | 2019 |
1 |
| 15 |
31448223 | New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia. | 2019 |
1 |
| 16 |
29325229 | Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance. | 2018 Mar |
1 |
| 17 |
29522367 | Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy. | 2018 Apr |
1 |
| 18 |
30137981 | Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. | 2018 Sep 27 |
3 |
| 19 |
28329763 | The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. | 2017 Mar 30 |
2 |